REFERENCES
- Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961; 31: 163–6.
- Donnis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851–6.
- Mulligan LM, Kwok JBJ, Healy CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458–60.
- Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia Type 2. International RET mutation consortium analysis. JAMA 1996; 276: 1575— 9.
- Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation systems (ARMS). Nucleic Acids Res 1989; 17: 2503–16.
- Ballabic A, Gibbs RA, Caskey CT. PCR test for cystic fibrosis deletion. Nature 1990; 343: 220.
- Krarup H, Drewes A, Madsen PH. Quantitative HCV-PCR. Scand J Clin Lab Invest 1998; 58: 415— 22.
- Gagel RF, Cote GJ, Martins Bugalho MJG, et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med 1995; 238: 333–41.
- Thakker RV, Ponder BAJ. Multiple endocrine neoplasia. Syndromes of the twentieth century. J Clin Endocrinol Metab 1998; 83: 2617–20.
- Lips CJM, Landsvater RM, Höppener JWM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia. N Engl J Med 1994; 331: 828–35.
- Wohllk N, Cote GJ, Evans BE, Goepfert H, Ordonez G, Gagel GF. Application of genetic information to the management of medullary thyroid carcinoma and multiple endocrine neo-plasia type 2. Endocrinol Metab Clin North Am 1996; 25: 1–25.